Drug intelligence / Profile preview

INND-201

Development stage: Preclinical
Lead developer: InnDura Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

INND-201 is a preclinical-stage immunotherapy being developed by InnDura Therapeutics for the treatment of multiple myeloma. It utilizes a CD7-targeted lipid nanoparticle (LNP) delivery system to transport mRNA encoding the EVE16 immune receptor into immune effector cells. The EVE16 receptor is constructed on a CD16A framework and is designed to redirect these effector cells to target and eliminate B-cell maturation antigen (BCMA)-expressing myeloma cells. This approach aims to provide a potent, off-the-shelf alternative to traditional CAR-T therapies by leveraging endogenous immune cells.

Other names: INND-201INND201INND 201

Targets

BCMA (B-cell maturation antigen)CD7 (CD7 antigen)

Beyond the preview

Go deeper on INND-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INND-201.

Explore the full profile